ArticleThe Eurasian journal of medicine2023
Investigation of Cytotoxic and Apoptotic Effects of Styrax Liquidus Obtained From Liquidambar orientalis Miller (Hamamelidaceae) on HEp-2 Cancer Cell with Caspase Pathway.
Article in The Eurasian journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Comprehensive Metabolomic Profiling and Biological Activity Analysis ofFood science & nutrition · 2025Article
- Wound Healing Effects of New Cream Formulations with Herbal Ingredients.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe HEp-2 cell line was first identified as laryngeal cancer cells. Then, it was reported to consist of cervical adenocarcinoma cells derived via HeLa cell line contamination. Styrax liquidus is an exudate that is provided by the injured hull of the Liquidambar orientalis Miller (Hamamelidaceae), which has been used for the treatment of skin problems, peptic ulcers, and parasitic infections or as an antiseptic. In our study, we purposed to research the cytotoxic and apoptotic effect of styrax liquidus on HEp-2 cancer cell line. MATERIALS AND
methodsThe IC50 dosage of styrax liquidus (Turkish sweet gum obtained from trees) was set by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, and the apoptotic effect of styrax liquidus on HEp-2 cancer cell was determined by assessing the expression of genes involved in apoptosis (Bax, Bad, Bak1, p53, Bcl-2, Bcl-XL, Apaf-1, Caspase2, Caspase3a, Caspase9, and Caspase12) by quantitative real-time polymerase chain reaction.
resultsThe IC50 value of styrax liquidus was found to be 125 μg/mL for 48 hours. According to the results, styrax liquidus reduced the population of HEp-2 laryngeal cancer cells and increased the expression of genes which were apoptosis related. These results indicate that styrax liquidus can be thought as a choice of cancer therapy.
conclusionThe finding of the study showed that it would be more useful to perform more qualified studies about the effect of styrax liquidus on cancer cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.